Drug intelligence / Profile preview

EBP-A.muc-DS3

Development stage: Preclinical
Lead developer: Enterobiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

EBP-A.muc-DS3 is a live biotherapeutic product (LBP) candidate developed by Enterobiome, utilizing the keystone gut bacterial species *Akkermansia muciniphila*. It is being developed as a dietary supplement specifically for metabolic diseases, including type 2 diabetes and related anti-diabetes indications. The mechanism of action involves the modulation of the gut microbiome and metabolic pathways to improve glucose regulation and metabolic health. Currently in the preclinical/MoA investigation stage, Enterobiome aims to advance the product with a projected timeline for registration or launch between 2026 and 2027.

Other names: Enterobiome-A.muciniphila-DS (metabolism/anti-diabetes)

Beyond the preview

Go deeper on EBP-A.muc-DS3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBP-A.muc-DS3.

Explore the full profile